Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors

Jung, Nam-Chul; Kim, Hee Jung; Kang, Mi-Sun; Lee, Jun-Ho; Song, Jie‐Young; Seo, Han Geuk; Bae, Yong-Soo; Lim, Dae‐Seog

doi:10.1016/j.canlet.2012.04.024

Cited by 43 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials have provided evidence that DC vaccines are able to elicit immunological responses; however, few complete tumor remissions have been reported (40). In order to improve the efficacy of DC vaccines, restoring or stimulating the immune response of the body against cancer may be an effective approach.…”

Section: Discussionmentioning

confidence: 99%

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens

Wang

Gao

Qin

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. As a key molecule involved in cell recognition, calreticulin (CRT) may be expressed on the surface of (pre-) apoptotic cells and provide the signal that is recognized by dendritic cells (DCs) or other antigen presenting cells (APCs), which results in phagocytosis. Within the APCs, tumor-associated antigens (TAAs) may be subsequently presented to T lymphocytes, which triggers a specific antitumor immune response. It has been hypothesized that CRT is able to act as the immunologic adjuvant and translocate itself and TAAs to the cell surface and induce a specific antitumor immune response. In the present study, CRT was demonstrated to translocate itself and mucin 1 (MUC1), a breast cancer antigen, to the surface of 4T1 cells and the MUC1-CRT-coated cells were able to induce apoptosis in a time-dependent manner. When DCs were infected with adenovirus containing MUC1-CRT, an increase in T cell proliferation and cytokine production was exhibited. These results suggest that CRT may act as an immunologic adjuvant with MUC1 and induce a strong immune response.

show abstract

Section: Discussionmentioning

confidence: 99%

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens

Wang

Gao

Qin

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Since DCs are important immune cells for uptaking, processing, and presenting tumor antigens, DC-based vaccines are an attractive approach to treat cancers [32][33][34]. Clinical trials provide evidence that DC vaccines can elicit immunological responses, yet few complete tumor remissions have been reported [22].…”

Section: Discussionmentioning

confidence: 99%

“…Mice treated with PDT-DCs had few, if any, tumors, whereas mice treated with PBS developed tumors. Moreover, PDT-DC vaccination induced an efficient tumor-specific CTL response and resulted in potent stimulation of IFN-γ-secreting CD8 + T cells [22]. In a 'classical' sense, the most immunogenic cell death pathway is necrosis, since rapid loss of plasma membrane integrity occurring during necrosis is associated with the release of various pro-inflammatory factors [23][24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma

Wang

2015

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

“…[47][48][49][50] DC-based treatment strategies are increasingly recognized to have therapeutic potential in many immunopathological conditions including cancer, autoimmunity, and allogeneic transplantation. [51][52][53][54][55][56][57] Early experiments had indicated that MENK acted as a novel biological treatment for advanced pancreatic cancer, colorectal cancer, 58 human hepatocellular cancer, 59 thyroid follicular cell-derived cancers, 60 and inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. 61 Moreover, PTD could stimulate the proliferation of human PBMCs from neoplastic donors.…”

Section: Discussionmentioning

confidence: 99%